Daiichi Life Insurance Co. Ltd. Invests $1.55 Million in Boston Scientific Corporation $BSX

Daiichi Life Insurance Co. Ltd. bought a new stake in Boston Scientific Corporation (NYSE:BSX) in the second quarter, Holdings Channel.com reports. The firm bought 36,343 shares of the medical equipment provider’s stock, valued at approximately $1,551,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of the business. Vanguard Group Inc. raised its holdings in Boston Scientific by 1.0% in the 4th quarter. Vanguard Group Inc. now owns 139,685,997 shares of the medical equipment provider’s stock valued at $13,319,060,000 after acquiring an additional 1,436,550 shares during the last quarter. BlackRock Inc. purchased a new position in Boston Scientific in the 2nd quarter worth approximately $5,534,781,000. State Street Corp boosted its holdings in shares of Boston Scientific by 1.4% during the 4th quarter. State Street Corp now owns 65,846,059 shares of the medical equipment provider’s stock worth $6,278,422,000 after purchasing an additional 920,495 shares during the last quarter. Capital World Investors boosted its holdings in shares of Boston Scientific by 1.9% during the 4th quarter. Capital World Investors now owns 27,151,575 shares of the medical equipment provider’s stock worth $2,588,953,000 after purchasing an additional 502,627 shares during the last quarter. Finally, Norges Bank purchased a new stake in shares of Boston Scientific in the fourth quarter valued at approximately $2,199,395,000. 89.07% of the stock is owned by hedge funds and other institutional investors.

Boston Scientific Stock Up 0.0%

Boston Scientific stock opened at $50.39 on Monday. The stock has a 50 day moving average of $46.34 and a two-hundred day moving average of $57.62. Boston Scientific Corporation has a twelve month low of $42.20 and a twelve month high of $109.50. The stock has a market capitalization of $73.03 billion, a price-to-earnings ratio of 20.40, a PEG ratio of 1.10 and a beta of 0.56. The company has a current ratio of 1.24, a quick ratio of 0.74 and a debt-to-equity ratio of 0.43.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.83 by $0.03. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The business had revenue of $5.44 billion for the quarter, compared to analyst estimates of $5.38 billion. During the same quarter in the previous year, the company posted $0.75 earnings per share. The company’s revenue for the quarter was up 7.5% compared to the same quarter last year. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, research analysts expect that Boston Scientific Corporation will post 3.3 earnings per share for the current year.

Boston Scientific announced that its board has authorized a share buyback plan on Monday, May 18th that allows the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization allows the medical equipment provider to repurchase up to 6.4% of its stock through open market purchases. Stock repurchase plans are usually an indication that the company’s board of directors believes its shares are undervalued.

Insiders Place Their Bets

In other news, CEO Michael F. Mahoney purchased 186,240 shares of the company’s stock in a transaction dated Monday, August 3rd. The shares were acquired at an average cost of $48.33 per share, for a total transaction of $9,000,979.20. Following the completion of the purchase, the chief executive officer directly owned 1,590,024 shares in the company, valued at $76,845,859.92. The trade was a 13.27% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Edward J. Ludwig acquired 5,000 shares of Boston Scientific stock in a transaction that occurred on Friday, July 31st. The stock was purchased at an average price of $45.48 per share, with a total value of $227,400.00. Following the transaction, the director owned 30,359 shares of the company’s stock, valued at $1,380,727.32. This trade represents a 19.72% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last quarter, insiders bought 194,522 shares of company stock worth $9,385,210. 0.34% of the stock is owned by insiders.

Wall Street Analyst Weigh In

BSX has been the subject of a number of recent research reports. Argus reaffirmed a “hold” rating on shares of Boston Scientific in a research note on Friday, July 31st. Wall Street Zen cut Boston Scientific from a “buy” rating to a “hold” rating in a report on Sunday, August 2nd. Evercore set a $65.00 price objective on Boston Scientific in a research report on Monday, July 6th. Bank of America lowered their price objective on shares of Boston Scientific from $105.00 to $68.00 and set a “buy” rating for the company in a research report on Monday, May 18th. Finally, BTIG Research lowered their target price on Boston Scientific from $65.00 to $60.00 and set a “buy” rating for the company in a report on Wednesday, July 29th. Twenty-four research analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $71.62.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.